Optivia Biotechnology Inc. Signs Agreement With U.S. FDA to Assess Role of Dietary Supplements in Drug-Induced Liver Injury

Published: Feb 01, 2011

MENLO PARK, Calif.--(BUSINESS WIRE)--Optivia Biotechnology Inc., a leading provider of in vitro transporter assay services, today announced that the company and the U.S. Food and Drug Administration (FDA) have signed a collaboration agreement to assess the effect of dietary supplements on key drug transporters. The goal of the collaboration is to identify potentially harmful drug-dietary supplement interactions, such as an interaction with acetaminophen and other drugs associated with liver toxicity.

Back to news